Impact of HPV vaccination on anogenital warts and respiratory papillomatosis
Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology
Infectious Disease | Pediatrics | Therapeutics | Virus Diseases
Human papillomavirus (HPV), the most common sexually transmitted infection in the US and worldwide, can cause cancers, anogenital warts (AGW), and recurrent respiratory papillomatosis (RRP) in men, women, and children. Global incidence of AGW ranges from 160-289 cases per 100,000 person-years and peaks in young men and women in the third decade of life. RRP has an estimated incidence of 3 per 1 million person-years in children. Pre-licensure trial efficacy, modeling and time-trend ecological studies have shown a significant short-term impact of 4vHPV vaccine. In girls aged 15-19 years, a previously published meta-analysis indicated that genital warts decreased significantly by 31%; stratified analysis revealed more substantial reductions in populations with high ( > /=50 %) vs. low ( < 50 % ) vaccination coverage (61% vs. 14%). Longer-term monitoring will reveal whether this impact continues under 9vHPV programs, and whether current declines in AGW are mirrored by declines in RRP.
anal warts, condylomata, genital warts, human papillomavirus vaccine impact, oral warts, respiratory papillomatosis
DOI of Published Version
Hum Vaccin Immunother. 2016 Jun 2;12(6):1357-62. doi: 10.1080/21645515.2016.1172754. Epub 2016 May 23. Link to article on publisher's site
Human vaccines and immunotherapeutics
Wangu, Zoon and Hsu, Katherine K., "Impact of HPV vaccination on anogenital warts and respiratory papillomatosis" (2016). Pediatric Publications and Presentations. 190.